Megalis is an India-market tadalafil product name associated with Macleods Pharmaceuticals. Indian medicine records identify Megalis 5, Megalis 10 and Megalis 20 tablets as tadalafil-containing presentations, and list Macleods as the marketer. Those observations are more informative than treating Megalis as an unspecified alternative to Cialis: the exact product name, tablet strength, market and responsible company all matter.
The available records support an India-market product identity, not FDA approval for Megalis-branded tablets. A patient seeking tadalafil in the United States should distinguish the approved active ingredient from an individually approved U.S. finished product. U.S. generic tadalafil products have their own application, label and dispensing requirements.
This page concentrates on Megalis and the role of Macleods, rather than repeating the tadalafil ingredient guide or providing an import-shopping route. The wider Indian tadalafil brand directory compares other India-market brand identities, while the lawful U.S. purchase process addresses U.S. prescriptions and regulated dispensing.
Strength-specific India pharmacy entries identify Megalis 5 mg, 10 mg and 20 mg with tadalafil as the active ingredient. These are three distinguishable listings, not evidence that every proposed Megalis variant or package is genuine. The records describe the marketed products in India and should not be copied into a U.S. FDA strengths inventory as if they were U.S. approvals.
In these listings the company field describes Macleods Pharmaceuticals as marketer. A retailer label is useful corroboration of the commercial association but does not independently prove which factory made a particular batch. A finished pack or authoritative manufacturer documentation would be needed to assign exact production roles.
| Named India-market listing | Declared ingredient | Evidence-supported attribution |
|---|---|---|
| Megalis 5 tablet | Tadalafil 5 mg | Macleods shown as marketer |
| Megalis 10 tablet | Tadalafil 10 mg | Macleods shown as marketer |
| Megalis 20 tablet | Tadalafil 20 mg | Macleods shown as marketer |
A tablet strength names the quantity of tadalafil in an identified tablet; it does not tell readers whether the product was intended for a daily schedule, occasional ED treatment or a different clinical context. In U.S. labeling, tadalafil has distinct daily and as-needed frameworks and indication-specific directions. That framework cannot be transferred to an imported pack without assessing its own label.
The purpose of listing the Megalis strengths is product identification, not selecting a stronger tablet. Clinicians review medicines, contraindications and goals before issuing any tadalafil prescription. For the U.S. distinctions, see tadalafil strength descriptions and daily versus as-needed treatment.
The Indian retailer records consistently give the marketer as Macleods Pharmaceuticals Pvt Ltd. “Marketer” is a specific supply-chain label and should not automatically be rewritten as finished-dose manufacturer, exporter or the holder of every claimed product approval. Company participation can vary between brands and individual presentations.
A trustworthy identity review records the trade name, ingredient, labeled strength, dosage form, responsible legal entity and exact market. A company-linked marketing claim can be cross-checked against packaging or regulatory filings, rather than treated as proof that every similarly named seller listing is authentic.
A complete Megalis listing should specify the active ingredient, tablet strength and route, rather than relying on the word “tadalafil” in a search snippet. Repackaged goods, copied photographs or incomplete product names can make different formulations look deceptively similar. Readers should treat missing or contradictory pack fields as a reason not to assume identity.
For U.S. prescriptions, the pharmacist can identify the product by its FDA-approved application, label and National Drug Code (NDC) where relevant. An NDC alone is not proof of FDA approval. A foreign-market Megalis listing must not be represented as interchangeable with an approved U.S. generic.
Cialis is a U.S.-approved tadalafil brand with its own prescribing information and labeled presentations. FDA-approved generic tadalafil products have separate approvals and applicable therapeutic-equivalence evaluations. By contrast, the cited Megalis material documents India-market commercial identity; it does not establish a U.S. Megalis application or an FDA equivalence rating.
Readers comparing the names should start with the Cialis brand page, then the approved generic guide to understand U.S. approval and substitution. Neither a shared active ingredient nor a similar-looking tablet supports assuming equal bioavailability across undocumented foreign formulations.
The evidenced Megalis 5, 10 and 20 tablet listings describe tadalafil as the active ingredient. That narrow finding should not be expanded to unspecified “Super,” “Plus,” oral-jelly or combination products that may appear in third-party searches. A suffix, unfamiliar form or an additional drug creates a materially different product-research question.
When an alleged variant lacks dependable ingredient and company documentation, mark it unverified rather than invent a strength or assume a combination. A second ingredient can create additional interactions and contraindications; combining treatment products cannot be justified by a brand-family name.
FDA approval attaches to specific product applications and not automatically to a drug ingredient approved in some other product. An Indian retailer offering Megalis is not evidence that Megalis can lawfully be dispensed in the United States. Foreign prescription-drug importation into the United States is subject to restrictive rules, and routine personal orders are not a substitute for domestic approval.
For U.S. treatment, the appropriate route remains a clinician-issued prescription filled by a licensed pharmacy. The tadalafil buying guide describes those steps. This page does not link to foreign purchase offers, quote transient listings or imply that shipped products pass U.S. regulatory controls.
Tadalafil is a PDE5 inhibitor and can lower blood pressure. It must not be taken with nitrates or riociguat, and other cardiovascular medicines can affect its safety. If the composition of a foreign product is uncertain, the question becomes more serious: neither strength nor authenticity can be inferred solely from the printed trade name.
Urgent care is necessary for an erection persisting more than four hours; sudden hearing or vision loss also requires prompt attention. The detailed interaction discussion belongs in the tadalafil interactions guide, not in claims that one India-market brand is intrinsically safer than another.
A useful due-diligence record preserves the exact Megalis product name, declared tadalafil amount, company-role wording and date of the underlying document. The Indian listings support the three identified strengths and marketer association; they do not independently authenticate a consumer pack, demonstrate present pharmacy stock or prove the final manufacturing facility.
If research reveals a new Megalis suffix or dosage form, verify it individually before amending the article. This evidence-limited approach is more valuable than a speculative brand catalogue. For context on other India-market products, compare Vidalista and Tadacip through their own documented product records.
Megalis is an India-market tadalafil product name. Identified Indian tablet listings include strengths of 5 mg, 10 mg and 20 mg, associated with Macleods as marketer.
Indian pharmacy product records identify Macleods Pharmaceuticals Pvt Ltd as marketer. That specific designation should not automatically be broadened into a claim about the factory responsible for every package.
The cited Megalis 10 tablet listing declares tadalafil 10 mg. That finding identifies the listed product, not an instruction to take that dose.
No. They are separately identified strength presentations, and their medical suitability depends on the actual label and individual prescription.
A foreign Megalis brand listing does not establish an FDA-approved U.S. application. Approval must be verified for the exact finished product.
No. Shared tadalafil content does not by itself establish FDA-approved therapeutic equivalence between a foreign-market Megalis product and U.S. Cialis.
The documented 5, 10 and 20 mg tablet listings identify tadalafil. Do not generalize that fact to unrelated or unverified names and dosage forms.
A clinician can evaluate whether an FDA-approved tadalafil product is appropriate and a licensed U.S. pharmacy can dispense it under a valid prescription.